Research

We fund and facilitate research for treatments so that more RET-positive lung cancer patients will live fuller, healthier lives.

Our researchers are investigating resistance to currently available targeted therapies, including: 

• Identifying new, more effective combination therapies for RET-inhibitor resistant disease 
• Testing innovative adaptive T cell therapies such as TCR immunotherapies for RET cancers
• Generating new RET cancer preclinical models, including cell likes and patient-derived xenograft mouse models

We also work closely with the offices of leading cancer research institutions to assist them in securing grant funding for continued RET-positive research. 

Since our inception in 2021, we have awarded more than $1 million in RET-positive cancer research grants and facilitated an additional $1 million in research funding.